Navigation Links
Lab on a chip developed at University of Alberta for cheap, portable medical tests
Date:1/29/2008

University of Alberta researchers in Edmonton, Canada, have developed a portable unit for genetic testing about the size of a shoebox, which has the same capability as a lab full of expensive equipment.

The device along with other, even smaller units the team is now in the process of developing paves the way for enormous savings to health-care systems and will improve care for patients. A wide variety of genetic tests that are available but not often used because their cost is prohibitive will become cheap, fast and easily accessible.

Prof. Christopher Backhouse, of the Department of Electrical and Computer Engineering, together with Dr. Linda Pilarski, an oncology professor in the Faculty of Medicine and Dentistry, and their research team, have received international recognition for the device. An article describing their shoebox-sized portable unit appears in the Jan. 18, 2008, issue of The Analyst, a scientific journal published by the Royal Society of Chemistry based in the United Kingdom. The article lead author is University of Alberta PhD student Govind V. Kaigala.

A royal society publication (Chemical Science) heralded the device in an online article featuring the advance, and indicated the University of Alberta is winning the global race to use micro and nano-biotechnology in developing diagnostic applications for so-called lab-on-chip technology.

It said:

Canadian scientists have succeeded in building the least expensive portable device for rapid genetic testing ever made. The cost of carrying out a single genetic test currently varies from hundreds to thousands of pounds, and the wait for results can take weeks. Now a group led by Christopher Backhouse, University of Alberta, Edmonton, have developed a reusable microchip-based system that costs just 500 (pounds) to build, is small enough to be portable, and can be used for point-of-care medical testing.

Backhouse compares the developm
'/>"/>

Contact: Julia Necheff
julia.necheff@ualberta.ca
780-492-0437
University of Alberta
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mouse Model of Age-Related Macular Degeneration Developed
2. Cancer cell line developed that is resistant to new cancer therapy
3. New system for classifying infant lung disease developed
4. Genomic technologies to identify toxic chemicals should be developed
5. New Denver Area Program Developed For Teens in Crisis
6. Mobility-enhancing device developed at University of Alberta will receive prestigious da Vinci Award
7. Lab-on-chip testing for bird flu developed by Singapore scientists
8. Microbiotic technology developed for microinjection of zebrafish embryos
9. JDRF to establish an autoimmunity center at University of Colorado Denver
10. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
11. Iowa State University researchers work on gender, temperature link in reptiles published in Nature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...S, N.J., Nov. 21 Today, ...l intervention in treating 88 percent of patients ...mericans treated for a chronic condition account f...d 75 percent of all medical costs. A proprietary ...edco Health Solutions, Inc. (NYSE: MHS ) signifi...
(Date:11/21/2008)... popular drugs do not cause genetic damage that ca...ealthDay News) -- Two popular medications for trea...D) do not cause genetic damage linked to an increa..., The study, done by researchers at Duke Univer... Health, counters a previous one that reported bio...
(Date:11/21/2008)..., a new and deadly diseaseits cause remains a myst...was teeming with citizens, soldiers and refugees o...s streets filled with corpses, social order broke ...ned twice and Athens lost a third of its populatio...d the beginning of the end of the Golden Age of Gr...
(Date:11/21/2008).... 21 /PRNewswire/ -- For the second year in a r...Cann Healthcare Worldwide,s agency network won mor... the 22nd annual international RX Club Show. , ...ices won a total of 59 RX Club Awards of Excellenc...Cann Healthcare Worldwide agencies include Caudex ...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
...anderbilt University Medical Center reveal a surpr...rt that the Golgi apparatus -- a stack of pancake... out to their cellular destinations -- is the sour...icroscopic fibers. Scientists have long thought t...
...sorder figures among seem to soar out of proportio...published in response to parliamentary questions ... children being hospitalized with eating disorders...cade. This mainly comprises of people under the ag...
... and women seeking surgical procedures among most ...oration procedures were performed worldwide in 200...cs released today from a recent member survey cond...ation Surgery (ISHRS) -- the world's leading medic...
...rnment took a step Wednesday toward offering vacci... as 12, a measure that could be carried out by la...and Immunisation (JCVI) recommended the use of vac... (HPV), a sexually transmitted infection which cau...
Other Medicine News:Health News:Research in the Origin of Microtubules 2Health News:Research in the Origin of Microtubules 3Health News:Eating Disorder Figures Among Children Soars 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 3Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2
(Date:11/20/2008)...ewswire/ -- Milk. It does a body good. And,now it...fter years of,research, scientists at OncoNutriti...lk that stimulate the body,s own production of ant...s Release, go to:, http://www.prnewswire.com/mnr/e...ew cancer therapies, the chief scientist, Dr. Davi...
(Date:11/20/2008)...-- Clinical data from a prospective,registry pres... shows DVT,treatment with the Trellis(R) Peripher...anta Clara, CA) successfully breaks up the blood c... This technique, called isolated pharmacomechanic... and safely than current catheter-directed thrombo...
(Date:11/19/2008)... Amgen,(Nasdaq: AMGN )...bsidiary of,Takeda Pharmaceutical Company Limited...the Phase 3 MONET1 trial evaluating motesanib (AMG...tin for the first-line treatment of,advanced non-...y suspended,following a planned safety data revie...
(Date:11/19/2008)...re/ -- Isogen, a contract development and,manufac...ounced the first,phase launch of its contract fac...ally address the process, facility and capacity pr...ghly-niched, low-volume clinical and,early-stage ... Companies can invest over $100 million and four ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2BioMarin Announces First Quarter 2008 Financial Results 4955 1BioMarin Announces First Quarter 2008 Financial Results 4955 2BioMarin Announces First Quarter 2008 Financial Results 4955 3BioMarin Announces First Quarter 2008 Financial Results 4955 4BioMarin Announces First Quarter 2008 Financial Results 4955 5BioMarin Announces First Quarter 2008 Financial Results 4955 6BioMarin Announces First Quarter 2008 Financial Results 4955 7BioMarin Announces First Quarter 2008 Financial Results 4955 8BioMarin Announces First Quarter 2008 Financial Results 4955 9BioMarin Announces First Quarter 2008 Financial Results 4955 10BioMarin Announces First Quarter 2008 Financial Results 4955 11Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 1Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 2Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 3Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 4Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4
... THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2...esults from a pivotal Phase 3,trial which showed t...clonal antibody directed against the epidermal gro...free survival (PFS) compared,to best supportive ca...who had failed fluoropyrimidine, irinotecan, and,o...
... ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A ... before last winter may have been,less effective t...adults who had flu shots before last winter were o...se who were not vaccinated. The,differences were l...ic.(1) In the winters of 2003/2004 and 2004/2005 a...
Other Medicine Technology:Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 2Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 3Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 4Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 6Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband.
A rapid rise in intracranial pressure requires early recognition, intervention and continuous monitoring. Ventrix utilizes state-of-the-art fiberoptic technology that gets to the source of pressure.
The Codman ICP Monitoring System provides highly accurate measurements of intracranial pressure at the source-subdural, parenchymal or intraventricular levels. The information is relayed electronical
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)
Medicine Products: